TP和GP方案治疗晚期非小细胞肺癌疗效观察

Clinical observation of docetaxel plus cisplatin versus gemcitabine plus cisplatin in treatment of advanced non-small cell lung caner

目的：比较多西他赛及吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的疗效和不良反应。方法：80例晚期非小细胞肺癌患者,随机分为2组。多西他赛组：多西他赛37.5 mg/m2,第1天、第8天,顺铂75 mg/m2,第2～4天。吉西他滨组：吉西他滨1 000 mg/m2,第1天、第8天,顺铂用量用法同前。化疗每3周重复,每次循环评价不良反应、生活质量,2次循环后评价疗效,并随访生存期。结果：多西他赛组有效率45.00%,吉西他滨组有效率42.50%,两组主要毒副作用为骨髓抑制、恶心、呕吐。结论：多西他赛及吉西他滨联合顺铂一线治疗晚期非小细胞肺癌疗效高。

Objective： To compare the efficacy and side effects of docetaxe｜/cisplatin regiment （DP） and gemcitabine/cisplatin regiment （GP） in treatment of advanced non-small cell lung cancer （NSCLC）. Methods： A total of 80 patients with advanced NSCLC were randomized into 2 groups. The patients in docetaxel group were received docetaxel at 37.5 mg/m2 on day 1 and day 8 ,cisplatin at 75 mg/m2 on day 2 to day 4. In gemcitabine group, the patients were received gemcitabine at 1 000 mg/m2 on day 1 and day 8, and the same method of cisplatin as in docetaxel group. The treatment schedule was recycled every 3 weeks. The toxicity and life quality were evaluated after every cycle. The efficacy and survival rate were evaluated at the end of two cycles. Results： The response rates in docetaxel group and gemcitabine group were 45.00% and 42.50% respectively. The main side effects were myelosuppression, nausea and vomiting. Conclusions ： Docetaxel/cisplatin and gemcitabine/cisplatin regiments had the high efficacys in treatment of advanced NSCLC patients.